Lou A. Bianco
Director/Board Member at DiaKine Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jack W. Singer | M | 81 |
DiaKine Therapeutics, Inc.
DiaKine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications. | 28 years |
Mary Ann Latona Nadler | F | - |
DiaKine Therapeutics, Inc.
DiaKine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications. | - |
Jerry L. Nadler | M | 71 |
DiaKine Therapeutics, Inc.
DiaKine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications. | - |
Jim B. Farinholt | M | - |
DiaKine Therapeutics, Inc.
DiaKine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications. | - |
Reed Tuckson | M | 73 | 13 years | |
Jim Fong | M | 62 | 16 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Richard L. Love | M | 81 | - | |
Bruce J. Seeley | M | 59 | 7 years | |
James A. Bianco | M | 67 | 25 years | |
Karen M. Ignagni | F | 70 | 22 years | |
Vartan Gregorian | M | 90 | 13 years | |
Russell Hawkinson | M | 65 | 1 years | |
Phillip M. Nudelman | M | 88 | 23 years | |
Michael Metzger | M | 53 | 6 years | |
Matthew Perry | M | 51 | 7 years | |
Mary O'Neil Mundinger | M | 87 | 19 years | |
Frederick Telling | M | 73 | 12 years | |
Richard E. Leigh | M | 64 | 1 years | |
Monique M. Greer | F | - | 4 years | |
John H. Bauer | M | 83 | 10 years | |
Steven E. Benner | M | 64 | 1 years | |
Scott Stromatt | M | 66 | 5 years | |
Nancy L. Boman | M | - | 8 years | |
Matthew J. Plunkett | M | 52 | 5 years | |
Edward Grant | M | 63 |
Deutsche Bank Capital Corp.
| 1 years |
Thayer White | M | - | 10 years | |
Craig Philips | M | 64 | 4 years | |
Kenny Crouch | M | - | - | |
Ed Bell | M | - | 10 years | |
Mauro G. Premi | M | - | - | |
Glenn C. Rice | M | 68 | 5 years | |
Jack L. Bowman | M | 91 | 9 years | |
Alberto Bernareggi | M | - | - | |
Christina A. Waters | M | - | - | |
Cynthia Shumate | F | 62 | 1 years | |
Bruce R. York | M | 69 | 1 years | |
Herbert J. Scheidt | M | 73 |
Deutsche Bank Capital Corp.
| 4 years |
Dorothy Senghas Lakner | M | - |
Deutsche Bank Capital Corp.
| 3 years |
Silvano Spinelli | M | 71 | - | |
Erich Maximilian Platzer | M | 74 | - | |
Stephen Aselage | M | 73 | 1 years | |
Edward F. Kenney | M | 79 | 5 years | |
John Fluke | M | 81 | 3 years | |
Daniel G. Eramian | M | 75 | 6 years | |
Jun Bao | M | 58 | 4 years | |
Warren E. Hall | M | 71 | 3 years | |
James Canfield | M | 66 | 4 years | |
Katherine Ruffner | M | - | 11 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 48 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lou A. Bianco
- Personal Network